2021
Biogen's Aduhelm was approved in June 2021, and by September 11, 2021 about 100 people had received it commercially outside clinical trials.
“Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial.”
Host · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:08:13
2021
Biogen priced Aduhelm at an average of $56,000 a year, which Damian Garde said added to skepticism about the drug.
“the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy”
Host · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:09:12
2023
Stelios Papadopoulos, Biogen's longtime chairman, is stepping back from the board because of the company's mandatory age retirement policy.
“Stelios Papadopoulos, the longtime chairman, is resigning from the war, stepping back from the board. And that's due to Biogen's mandatory age retirement policy.”
Adam Feuerstein · 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid, 0:07:56
2023
John Reed replaces Mathai Mammen at Johnson & Johnson; Mammen was briefly a candidate for the Biogen CEO position before leaving J&J's top research role.
“he's replacing Matai Mamon, who we've spoken about, was briefly a candidate for the Biogen CEO position”
Damian Garde · 246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid, 0:10:40
Undated
Karaboutis notes her experience includes senior roles at Dell, Biogen and National Grid before becoming an independent board member.
“I've been doing boards for ten years”
Adriana Karaboutis · Enterprise AI: A Board of Directors Perspective | #866, 0:34:14
Undated
Koller refers to a Biogen drug for SOD1 ALS patients that was provisionally approved and reportedly reverses disease in some patients.
“This is a biogen drug specifically against SOD1 patients”
Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:44:14